Synthesis, Activity, and Pharmacophore Development for Isatin-β-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells
Authors:
- Noeris K. SalamNSNoeris K. Salam
- Jennifer L. HellawellJHJennifer L. Hellawell
- Henry M. FalesHFHenry M. Fales
- Caroline B. KenslerCKCaroline B. Kensler
- Joseph A. LudwigJLJoseph A. Ludwig
- Gergely SzakácsGSGergely Szakács
- David E. HibbsDHDavid E. Hibbs
- Michael M. GottesmanMGMichael M. Gottesman
- 27 April 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (10) , 3191-3204
Abstract
We have recently identified a new class of compounds that selectively kill cells that express P-glycoprotein (P-gp, MDR1), the ATPase efflux pump that confers multidrug resistance on cancer cells. Several isatin-β-thiosemicarbazones from our initial study have been validated and a range of analogues synthesized and tested. A number demonstrated improved MDR1-selective activity over the lead, NSC73306 (1). Pharmacophores for cytotoxicity and MDR1 selectivity were generated to delineate the structural features required for activity. The MDR1-selective pharmacophore highlights the importance of aromatic/hydrophobic features at the N4 position of the thiosemicarbazone and the reliance on the isatin moiety as key bioisosteric contributors. Additionally, a quantitative structure−activity relationship (QSAR) model that yielded a cross-validated correlation coefficient of 0.85 effectively predicts the cytotoxicity of untested thiosemicarbazones. Together, the models serve as effective approaches for predicting structures with MDR1-selective activity and aid in directing the search for the mechanism of action of 1.Keywords
This publication has 41 references indexed in Scilit:
- Identification of Compounds Selectively Killing Multidrug-Resistant Cancer CellsCancer Research, 2009
- Pharmacophore-based discovery of ligands for drug transportersAdvanced Drug Delivery Reviews, 2006
- A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeuticsProceedings of the National Academy of Sciences, 2006
- Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in CancerCancer Research, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and CancerPharmacological Reviews, 2005
- Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine KinaseJournal of Medicinal Chemistry, 2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Interaction of DNA with anti-cancer drugs: copper-thiosemicarbazide systemBioinorganic Chemistry, 1977
- Oxidative Reactions of Hydrazines. IV. Elimination of Nitrogen from 1,1-Disubstituted-2-arenesulfonhydrazides1-4Journal of the American Chemical Society, 1957